Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

Cited by (1,002)

Items 601–700 of 1,002

1. Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications
   Matthias Scheffler, Marcel Wiesweg, Sebastian Yves Friedrich Michels, Lucia Nogová, Anna Kron, Thomas Herold, Andreas Hans Scheel, Martin Metzenmacher, Wilfried Eberhardt, Henning Reis et al. · 2022 · Lung Cancer
2. Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review
   Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, Angela Listì, Edoardo Garbo, Giorgio V. Scagliotti · 2022 · Translational Lung Cancer Research
3. Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
   Kari Braun Wisinski, Yael Flamand, Melissa Ann Wilson, Jason J. Luke, Hussein A. Tawbi, Fangxin Hong, Edith Peterson Mitchell, James A. Zwiebel, Helen Chen, Robert J. Gray et al. · 2023 · JCO Precision Oncology
4. Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
   Terufumi Kato, Ignacio Casarini, Manuel Cobo, Corinne Faivre Finn, Fiona Hegi‐Johnson, Shun Lü, Mustafa Özgüroğlu, Suresh S. Ramalingam · 2023 · Lung Cancer
5. Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
   Jianghua Ding, Xingjing Ding, Jiao Zeng, Xiaoqun Liu · 2024 · Frontiers in Pharmacology
6. A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice
   Hollis Viray, Andrew J. Piper‐Vallillo, Page C. Widick, Emmeline C. Academia, Meghan Shea, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel Botelho Costa · 2024 · Cancers
7. New Treatment Options for Patients With Oncogene-Addicted Non–Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors
   Stephanie P.L. Saw, Xiuning Le, Lizza E.L. Hendriks, Jordi Remón · 2024 · American Society of Clinical Oncology Educational Book
8. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
   Ryota Nakamura, Tadaaki Yamada, Shinsaku Tokuda, Kenji Morimoto, Yuki Katayama, Yohei Matsui, Soichi Hirai, Masaki Ishida, Hayato Kawachi, Ryo Sawada et al. · 2024 · Cancer Letters
9. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors
   Eric Nadler, Melissa Pavilack, Janet L. Espirito, Jamyia Clark, Ancilla W. Fernandes · 2020 · Advances in Therapy
10. RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
    Badi Edmond El Osta, Suresh S. Ramalingam · 2020 · JTO Clinical and Research Reports
11. Ubiquitin ligase SMURF2 enhances epidermal growth factor receptor stability and tyrosine-kinase inhibitor resistance
    Paramita Ray, Krishnan Raghunathan, Aarif Ahsan, Uday Sankar Allam, Shirish Shukla, Venkatesha Basrur, Sarah L. Veatch, Theodore Steven Lawrence, Mukesh Kumar Nyati, Dipankar Ray · 2020 · Journal of Biological Chemistry
12. Detection of Tumor-Associated Membrane Receptors on Extracellular Vesicles from Non-Small Cell Lung Cancer Patients via Immuno-PCR
    Christiane Stiller, Kristina Viktorsson, Elizabeth Paz Gomero, Petra Hååg, Vasiliki Arapi, Vitaliy O. Kaminskyy, Caroline Kamali, Luigi De Petris, Simon Ekman, Rolf Lewensohn et al. · 2021 · Cancers
13. Chinese Herbal Medicine Combined With First-Generation EGFR-TKIs in Treatment of Advanced Non-Small Cell Lung Cancer With EGFR Sensitizing Mutation: A Systematic Review and Meta-Analysis
    Yan Lu, Chenbing Sun, Lijing Jiao, Yu Liu, Yabin Gong, Ling Xu · 2021 · Frontiers in Pharmacology
14. Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer
    Liu, Xiaoke, Hong, Lingzhi, Nilsson, Monique, Hubert, Shawna Marie, Wu, Shuhong, Rinsurongkawong, Waree, Lewis, Jeffery, Spelman, Amy, Roth, Jack, Swisher, Steven et al. · 2020 · Lung Cancer
15. Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations
    Yuki Takeyasu, Tatsuya Yoshida, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe · 2024 · JTO Clinical and Research Reports
16. A Prospective Phase II Trial of First-Line Osimertinib for Patients With EGFR Mutation-Positive NSCLC and Poor Performance Status (OPEN/TORG2040)
    Tomoya Fukui, Nobuaki Mamesaya, Toshiaki Takahashi, Kazuma Kishi, Takahiro Yoshizawa, Takaaki Tokito, Koichi Azuma, Kei Morikawa, Satoshi Igawa, Yusuke Okuma et al. · 2025 · Journal of Thoracic Oncology
17. Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer
    Donatella Romaniello, Alessandra Morselli, Ilaria Marrocco · 2025 · International Journal of Molecular Sciences
18. Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry
    Xin Xiong, Yuanyuan Zhang, Ziyu Wang, Congya Zhou, Ping Yang, Xin Du, Li Yang, Wei Liu · 2022 · Clinica Chimica Acta
19. Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
    Christopher A. Lemmon, Emily Craig Zabor, Nathan A. Pennell · 2022 · The Oncologist
20. Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF)
    Laurent Greillier, Manon Gauvrit, Éléna Paillaud, Nicolas Girard, Coline Montégut, Rabia Boulahssass, Marie Wislez, Frédéric Pamoukdjian, R. Corre, Mathilde Cabart et al. · 2022 · Cancers
21. Cardiovascular Risks with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors and Monoclonal Antibody Therapy
    Kalyan R. Chitturi, Ethan Alexander Burns, Ibrahim N. Muhsen, Kartik Anand, Barry H. Trachtenberg · 2022 · Current Oncology Reports
22. Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
    John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi S. Kuo, Ping‐Chih Hsu, Chiao‐En Wu · 2022 · Cancers
23. Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers
    Chao-Yu Liu, Heng-Fu Lin, Wei-Yi Lai, Yi-Ying Lin, Tzu-Wei Lin, Yi-Ping Yang, Fu-Ting Tsai, Chia-Lin Wang, Yung-Hung Luo, Yuh-Min Chen et al. · 2022 · Journal of the Chinese Medical Association
24. Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
    Xiaoyu Qian, Xiaodan Guo, Ting Li, Wei Hu, Lin Zhang, Caisheng Wu, Feng Ye · 2022 · Frontiers in Pharmacology
25. And Still They Come Over Troubled Waters: Can Asia’s Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC
    Sally C. M. Lau, Sai‐Hong Ignatius Ou · 2022 · Journal of Thoracic Oncology
26. Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center
    Camilla Nero, Simona Duranti, Flavia Giacomini, Angelo Minucci, Luciano Giacò, Alessia Piermattei, Maurizio Genuardi, Tina Pasciuto, Andrea Urbani, Gennaro Daniele et al. · 2022 · Journal of Personalized Medicine
27. Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
    John Wen‐Cheng Chang, Chen‐Yang Huang, Yueh‐Fu Fang, Ching‐Fu Chang, Cheng‐Ta Yang, Chih‐Hsi S. Kuo, Ping‐Chih Hsu, Chiao‐En Wu · 2022 · Thoracic Cancer
28. Extended Survival in Patients With Non–Small-Cell Lung Cancer–Associated Brain Metastases in the Modern Era
    Assaf Berger, Reed Mullen, Kenneth Bernstein, Juan Diego Alzate, Joshua Seth Silverman, Erik P. Sulman, Bernadine R. Donahue, Abraham Chachoua, Elaine Shum, Vamsidhar Velcheti et al. · 2023 · Neurosurgery
29. Progress and challenges in RET-targeted cancer therapy
    Xueqing Hu, Ujjwol Khatri, Tao Shen, Jie Wu · 2023 · Frontiers of Medicine
30. Propionate reinforces epithelial identity and reduces aggressiveness of lung carcinoma
    Vignesh Ramesh, Paradesi Naidu Gollavilli, Luisa Pinna, Aarif Siddiqui, Adriana Martinez-Turtos, Francesca Napoli, Yasmin Antonelli, Aldo Leal‐Egaña, Jesper Foged Havelund, Simon T. Jakobsen et al. · 2023 · EMBO Molecular Medicine
31. Immunotherapy in patients with brain metastasis: advances and challenges for the treatment and the application of circulating biomarkers
    Elena Brozos-Vázquez, C. Rodríguez-López, A. Cortegoso-Mosquera, S. López-Landrove, Laura Muinelo‐Romay, Jorge García, Rafael López‐López, Luis León‐Mateos · 2023 · Frontiers in Immunology
32. Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC
    Eun Ji Lee, Seung Yeon Oh, You Won Lee, Ju Young Kim, Min-Je Kim, Tae Ho Kim, Jii Bum Lee, Min Hee Hong, Sun Min Lim, Anke Baum et al. · 2024 · Clinical Cancer Research
33. The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population
    Sibo Liu, Nicholas Graves, Aaron C. Tan · 2024 · Lung Cancer
34. Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC)
    Bhatu R. Patil, Kunal Bhadane, Iqrar Ahmad, Yogesh Agrawal, Amit A. Shimpi, Mayur S. Dhangar, Harun Patel · 2024 · Bioorganic & Medicinal Chemistry
35. Non-small-cell lung cancer brain metastases and PD-(L)1 immune checkpoint inhibitors
    Fabrice Barlési, Pascale Tomasini · 2020 · The Lancet Oncology
36. Efficacy of immunotherapy in KRAS -mutant non-small-cell lung cancer with comutations
    Alexander P. Davis, Wendy A. Cooper, Michael Joseph Boyer, Jenny Lee, Nick Pavlakis, Steven Kao · 2021 · Immunotherapy
37. A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
    Qing Zhou, Lin Wu, Pei Hu, Tongtong An, Jianying Zhou, Li Zhang, Xiao-Qing Liu, Feng Luo, Xin Zheng, Ying Cheng et al. · 2021 · Clinical Cancer Research
38. Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer
    Dominika Kaźmierczak, Inger Johanne Zwicky Eide, Radosveta Gencheva, Yi Chun Lai, Rolf Lewensohn, Georgios Tsakonas, Oscar Grundberg, Luigi De Petris, Marc McGowan, Odd Terje Brustugun et al. · 2022 · Translational Lung Cancer Research
39. Cardiac Events and Survival in Patients With EGFR-Mutant Non–Small Cell Lung Cancer Treated With Osimertinib
    Chien‐Yu Lin, Wei-Ting Chang, Po‐Lan Su, Chin‐Wei Kuo, J.C. Yang, Chien‐Chung Lin, Sheng-Hsiang Lin · 2024 · JAMA Network Open
40. Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA
    Se-Hoon Lee, Shun Lü, Hidetoshi Hayashi, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Yu Jung Kim, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu et al. · 2025 · Journal of Thoracic Oncology
41. Unresectable stage III non-small-cell lung cancer: state of the art and challenges
    Jordi Remón, Antonin Lévy, Romane Gille, Isabelle Martel‐Lafay, Martina Bortolot, Lizza E.L. Hendriks, Corinne Faivre Finn, Natasha B. Leighl, Martin Reck, Maurice Pérol · 2025 · Nature Reviews Clinical Oncology
42. SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
    Leiming Xia, Fan Yang, Xiao Qin Wu, Suzhi Li, Chen Kan, Hong Zheng, Siying Wang · 2021 · Cancer Cell International
43. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
    Chiao‐En Wu, Ching‐Fu Chang, Chen‐Yang Huang, Cheng‐Ta Yang, Chih‐Hsi S. Kuo, Ping‐Chih Hsu, John Wen‐Cheng Chang · 2021 · BMC Cancer
44. Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment
    Soohyun Hwang, Tae Hee Hong, Sehhoon Park, Hyun Ae Jung, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Yoon‐La Choi, Se‐Hoon Lee · 2021 · Translational Lung Cancer Research
45. Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial
    Mariona Riudavets, Marie Naigeon, Matthieu Texier, Miriam Dorta, Fabrice Barlési, Julien Mazières, Andrea Varga, Lydie Cassard, Lisa Boselli, Jonathan Grivel et al. · 2021 · Lung Cancer
46. Real‐world treatment patterns of metastatic non‐small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors
    Rahul A. Shenolikar, Sizhu Liu, Anne Shah, Jenny Y. M. Tse, Yao Cao, Aimee M. Near · 2022 · Cancer Medicine
47. Prognostic communication about lung cancer in the precision oncology era: A multiple‐perspective qualitative study
    Laura A. Petrillo, Sophia Shimer, Ashley Z. Zhou, Robert K. Sommer, Jill Feldman, Kelly E. Hsu, Joseph Andrew Greer, Lara N. Traeger, Jennifer S. Temel · 2022 · Cancer
48. Novel anilinopyrimidine derivatives as potential EGFRT790M/C797S Inhibitors: Design, Synthesis, biological activity study
    Yanliang Guo, Biao Gao, Peng Gao, Lei Fang, Shaohua Gou · 2022 · Bioorganic & Medicinal Chemistry
49. Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study
    Daniel S.W. Tan, Sang‐We Kim, Santiago Ponce-Aix, Lecia Van Dam Sequist, Egbert Frederik Smit, James Chih‐Hsin Yang, Toyoaki Hida, Ryo Toyozawa, Enriqueta Felip, Juergen Wolf et al. · 2022 · European Journal of Cancer
50. Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China
    Yamin Shu, Yufeng Ding, Xucheng He, Yanxin Liu, Pan Wu, Qilin Zhang · 2022 · Frontiers in Pharmacology
51. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada
    M. Sara Kuruvilla, Geoffrey Liu, Iqra A. Syed, Femida hussein Gwadry-Sridhar, Brandon S. Sheffield, Robin Sachdeva, Alec Pencz, Luna Jia Zhan, Katrina Hueniken, Devalben Patel et al. · 2022 · Lung Cancer
52. Therapeutic potential for P2Y2 receptor antagonism
    Kimberly J. Jasmer, Kevin Muñoz Forti, Lucas T. Woods, Seunghee Cha, Gary A. Weisman · 2022 · Purinergic Signalling
53. CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer
    Suresh Bugide, Yvonne J. K. Edwards, Romi Gupta, Michael R. Green, Narendra Wajapeyee · 2023 · Proceedings of the National Academy of Sciences
54. Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
    Gian Marco Leone, Saverio Candido, Alessandro Lavoro, Silvia Vivarelli, Giuseppe Gattuso, Daniela Cornelia Călina, Massimo Libra, Luca Falzone · 2023 · Pharmaceutics
55. Indole Antitumor Agents in Nanotechnology Formulations: An Overview
    Eleonora Russo, Carola Grondona, Chiara Brullo, Andrea Spallarossa, Carla Villa, Bruno Tasso · 2023 · Pharmaceutics
56. Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial
    Shun Lü, Hongming Pan, Lin Wu, Yu Yao, Jianxing He, Yan Wang, Xiuwen Wang, Yong Fang, Zhen Xian Zhou, Xicheng Wang et al. · 2023 · Signal Transduction and Targeted Therapy
57. Targeted therapies in non-small cell lung cancer: present and future
    Jessica McLaughlin, Jonathan David Berkman, Patrick S. Nana-Sinkam · 2023 · Faculty Reviews
58. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
    A. Schuler, J. Huser, Sabine Schmid, Sämi Schär, Amina Scherz, Oliver Pascal Gautschi, Laetitia Arja Mauti, Thomas von Briel, Christine Waibel, Luciano Wannesson et al. · 2023 · Lung Cancer
59. Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
    Jiameng Lu, Xiaoqing Ji, Xinyi Liu, Yunxiu Jiang, Gang Li, Ping Fang, Wei Li, Anli Zuo, Zihan Guo, Shuran Yang et al. · 2024 · Scientific Reports
60. Evolving Precision First-Line Systemic Treatment for Patients with Unresectable Non-Small Cell Lung Cancer
    Tianhong Li, Weijie Ma, Ebaa Al-Obeidi · 2024 · Cancers
61. Advances in Personalized Oncology
    Hiba Mechahougui, James Gutmans, Gina Colarusso, Roumaïssa Gouasmi, Alex Friedlaender · 2024 · Cancers
62. First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial
    Qing Hua Zhou, Yan Yu, Ligang Xing, Ying Cheng, Ying Wang, Yueyin Pan, Yun Fan, Jianhua Shi, Guojun Zhang, Jiuwei Cui et al. · 2024 · Med
63. Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma
    Rui Li, Xiaofei Zhou, Hong-Juan Yao, Liang Li · 2020 · Journal of drug targeting
64. Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
    Taihei Ono, Satoshi Igawa, Shintaro Kurahayashi, Yuriko Okuma, Ai Sugimoto, Seiichiro Kusuhara, Takahiro Ozawa, Tomoya Fukui, Jiichiro Sasaki, Hisashi Mitsufuji et al. · 2020 · Investigational New Drugs
65. Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study
    Yuqing Lou, Jianlin Xu, Yanwei Zhang, Jun Lü, Tianqing Chu, Xueyan Zhang, Huimin Wang, Hua Zhong, Wei Zhang, Baohui Han · 2020 · Targeted Oncology
66. Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations
    Haiyan Xu, Weihua Li, Guangjian Yang, Junling Li, Lu Yang, Fei Xu, Yaning Yang, Jianming Ying, Yan Wang · 2020 · Targeted Oncology
67. Adult precision medicine: learning from the past to enhance the future
    Ashley Parham Ghiaseddin, Lan Hoang-Minh, Michalina Janiszewska, David H. Shin, Wolfgang Wick, Duane A. Mitchell, Patrick Yung Wen, Stuart A. Grossman · 2020 · Neuro-Oncology Advances
68. New lung-cancer drugs extend survival times
    Michael S. Eisenstein · 2020 · Nature
69. Almonertinib-induced interstitial lung disease
    Ting Jiang, Yiyang Luo, Binbin Wang · 2021 · Medicine
70. Identification of SLC38A7 as a Prognostic Marker and Potential Therapeutic Target of Lung Squamous Cell Carcinoma
    Naoki Haratake, Qingjiang Hu, Tatsuro Okamoto, Tomoko Jogo, Gouji Toyokawa, Fumihiko Kinoshita, Tomoyoshi Takenaka, Tetsuzo Tagawa, Norifumi Iseda, Shinji Itoh et al. · 2021 · Annals of Surgery
71. Prognostic influence of epidermal growth factor receptor mutation and radiological ground glass appearance in patients with early-stage lung adenocarcinoma
    Keiju Aokage, Tomohiro Miyoshi, Masashi Wakabayashi, Takashi Ikeno, Jun Suzuki, Kenta Tane, Joji Samejima, Masahiro Tsuboi · 2021 · Lung Cancer
72. Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer
    Pınar Ö. Eser, Raymond M. Paranal, Jieun Son, Elena V. Ivanova, Yanan Kuang, Heidi M. Haikala, Ciric To, Jeffrey J. Okoro, Kshiti H. Dholakia, Jihyun Choi et al. · 2021 · Science Translational Medicine
73. LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma
    Jianghua Ding, Xinjing Ding, Zhaohui Leng · 2022 · Journal of Cancer
74. Comparison of next‐generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations
    Shuji Murakami, Tomoyuki Yokose, Kanako Shinada, Testuya Isaka, Kengo Katakura, Ryouta Ushio, Tetsuro Kondo, Terufumi Kato, Hiroyuki Ito, Haruhiro Saito · 2022 · Thoracic Cancer
75. Patients with non‑small cell lung cancer with the exon 21 L858R mutation: From distinct mechanisms to epidermal growth factor receptor tyrosine kinase inhibitor treatments (Review)
    Jiayu Liu, Shouzheng Wang, Hanqi Yuan, Junling Li, Puyuan Xing · 2024 · Oncology Letters
76. Comprehensive PTM profiling with SCASP-PTM uncovers mechanisms of p62 degradation and ALDOA-mediated tumor progression
    Zhan-Peng Lin, Guohong Gan, Xiao Xu, Chengwen Wen, Xin Ding, Xiangyu Chen, Kaijie Zhang, Wenyu Guo, Mingxin Lin, Yu-Yang Wang et al. · 2025 · Cell Reports
77. Osimertinib plus consolidative radiotherapy for advanced EGFR mutant non–small cell lung cancer: a multicentre, single-arm, phase 2 trial
    Sagus Sampath, Sawsan Rashdan, Puneeth Iyengar, Townes A Mickel, Song Zhang, Chul Woo Ahn, Ang Gao, Jonathan E. Dowell, Yuanyuan Zhang, Kenneth D. Westover et al. · 2025 · EClinicalMedicine
78. The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database
    David Paul Carbone, Fred R Hirsch, Raymond Uyiosa Osarogiagbon, Katherine K. Nishimura, Ming‐Sound Tsao, William David Travis, Dawei Yang, Soo‐Ryum Yang, Yasushi Yatabe, Luiz Henrique Araujo et al. · 2025 · Journal of Thoracic Oncology
79. The Comprehensive Analyses of Genomic Variations and Assessment of TMB and PD-L1 Expression in Chinese Lung Adenosquamous Carcinoma
    Yong Cheng, Yanxiang Zhang, Yuwei Yuan, Jiao Wang, Ke Liu, Bin Yu, Li Xie, Chao Ou-Yang, Lin Wu, Xiaoqun Ye · 2021 · Frontiers in Genetics
80. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers
    Alice Boilève, Loïc Verlingue, Antoine Hollebecque, Valérie Boige, Michel Pierre Ducreux, David Malka · 2021 · Expert Opinion on Investigational Drugs
81. Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer
    Mei Elsayed, Farastuk Bozorgmehr, Daniel N. Kazdal, Anna‐Lena Volckmar, Holger Sültmann, Jürgen R. Fischer, Mark Kriegsmann, Albrecht Stenzinger, Michael Thomas, Petros Christopoulos · 2021 · Frontiers in Oncology
82. Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non–Small-Cell Lung Cancer
    Michael J. Harvey, Rachel Cunningham, Bethany Sawchyn, Meagan Montesion, Prasanth Reddy, Ali McBride, Anita Chawla · 2021 · JCO Precision Oncology
83. Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel IntergenicANK3-RETFusion inEGFR-Mutated Non–Small-Cell Lung Cancer
    Edyta Maria Urbanska, Jens Benn Sørensen, Linea Cecilie Melchior, Junia Cardoso Costa, Eric Santoni‐Rugiu · 2022 · JCO Precision Oncology
84. Retrospective analysis of independent predictors of progression‐free survival in patients with EGFR mutation‐positive advanced non‐small cell lung cancer receiving first‐line osimertinib
    Shuhei Teranishi, Chihiro Sugimoto, Satoshi Nagaoka, Hirokazu Nagayama, Wataru Segawa, Atsushi Miyasaka, Shuntaro Hiro, Yukihito Kajita, Chihiro Maeda, Nobuaki Kobayashi et al. · 2022 · Thoracic Cancer
85. Quality of Life and Cognitive Function Evaluations and Interventions for Patients with Brain Metastases in the Radiation Oncology Clinic
    Jennifer K. Matsui, Haley Kopp Perlow, Cyril Baiyee, Alex R. Ritter, Mark Vikas Mishra, Joseph A. Bovi, Vinai Gondi, Paul D. Brown, Ashlee R. Loughan, Heather E. Leeper et al. · 2022 · Cancers
86. EGFR inhibition in EGFR ‐mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment
    Akihiko Shiiya, Takuro Noguchi, Utano Tomaru, Shin Ariga, Yuta Takashima, Yoshihito Ohhara, Jun Taguchi, Satoshi Takeuchi, Yasushi Shimizu, Ichiro Kinoshita et al. · 2022 · Cancer Science
87. Navigating patient journey in early diagnosis of lung cancer in India
    Bivas Biswas, Deepak Talwar, Priti Lokesh Meshram, Pramod K Julka, Anurag Mehta, S. P. Somashekhar, Srinivas C. Chilukuri, Abhishek Bansal · 2022 · Lung India
88. Personalized treatment for patients with lung cancer
    Martin Schüler, Servet Bölükbas, Kaid Darwiche, Dirk Theegarten, Ken Herrmann, Martin Stuschke · 2023 · Deutsches Ärzteblatt international
89. Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions
    Jia Zhong, Hua Bai, Zhijie Wang, Jianchun Duan, Wei Zhuang, Di Wang, Rui Wan, Jiachen Xu, Kailun Fei, Zixiao Ma et al. · 2023 · Frontiers of Medicine
90. Taking early preventive interventions to manage the challenging issue of acquired resistance to third-generation EGFR inhibitors
    Shi‐Yong Sun · 2023 · Chinese Medical Journal - Pulmonary and Critical Care Medicine
91. Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment
    Chao Wang, Kailun Fei, Lihui Liu, Jianchun Duan, Zhijie Wang, Sini Li, Jiachen Xu, Xue Zhang, Yanhua Tian, Yan Qu et al. · 2023 · Thoracic Cancer
92. Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC
    Bin Liu, Feng Gao, Hui Zhao, Shuai Yuan, Xingzhe Peng, Pengzhi Zhang, Jing Wang, Tongmei Zhang, Maosheng Duan, Yongqi Guo · 2023 · European Journal of Medicinal Chemistry
93. The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non–Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis
    Jeroen Paul Jansen, Meera Vimala Ragavan, Cheng Chen, Michael P. Douglas, Kathryn A. Phillips · 2023 · Value in Health
94. The development of amivantamab for the treatment of non-small cell lung cancer
    Danielle Brazel, Misako Nagasaka · 2023 · Respiratory Research
95. Natural Product-Based Glycolysis Inhibitors as a Therapeutic Strategy for Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
    Wonyoung Park, Jung Ho Han, Shibo Wei, Eun-Sun Yang, Se-Yun Cheon, Sung‐Jin Bae, Dongryeol Ryu, Hwan‐Suck Chung, Ki‐Tae Ha · 2024 · International Journal of Molecular Sciences
96. A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE
    Lavinia Tan, Chris S. B. Brown, Antony J. Mersiades, Chee Khoon Lee, Thomas John, Steven Kao, Genni M Newnham, Kenneth John O'Byrne, Sagun Parakh, Victoria Bray et al. · 2024 · Nature Communications
97. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
    Seda Kahraman, Serdar Karakaya, Kaplan Ma, Sema Sezgin Göksu, Akın Öztürk, Zehra Sucuoğlu İşleyen, Jamshid Hamdard, Sedat Yildirim, Tolga Doğan, Selver Işık et al. · 2024 · Scientific Reports
98. Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date
    Olivier Bylicki, Nicolas Paleiron, Jean‐Baptiste Assié, CHRISTOS CHOUAID · 2020 · OncoTargets and Therapy
99. Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
    Roxana Reyes, Noemı́ Reguart · 2021 · Translational Lung Cancer Research
100. Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations
     Kartik Sehgal, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel Botelho Costa · 2020 · The Oncologist